Business
Acurx Announces Results of Its Pioneering Research with Ibezapolstat in Collaboration with Leiden University Medical Center at the Premier International C. difficile Symposium
Results feature high-resolution elucidation of interaction of ibezapolstat with its molecular target Mechanistic findings explain ibezapolstat's properties of
About this update from Acurx Pharmaceuticals, Inc.
[{"type":"text","content":"Results feature high-resolution elucidation of interaction of ibezapolstat with its molecular target Mechanistic findings explain ibezapolstat's properties of lacking cross resistance with other antibiotics and not fostering the emergence of Enterococcus, including vancomycin-resistant strains, a unique differentiation among anti-CDI antibioticsMolecular structure data will be used to guide rational design of new systemic therapeutic compounds with improved inhibitory activity and PK characteristicsPlanning continues to prepare to advance ibezapolstat into international Phase 3 clinical trials for treatment of C. difficile Infection (CDI)Acurx is also preparing requests for regulatory guidance to initiate clinical trials in the European Union, the United Kingdom, Japan and CanadaIbezapolstat has previously received FDA QIDP and Fast-Track Designation from FDASTATEN ISLAND, N.Y., Sept. 24, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (\"Acurx\" or the \"Company\"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced results from its pioneering research with ibezapolstat in collaboration with Leiden University Medical Center (LUMC). These results were presented at the premier International C. difficile Symposium (ICDS) held in Bled, Slovenia on September 17-19, 2024. Dr. Wiep Klaas Smits, PhD, Associate Professor, LUMC, delivered a presentation entitled: Structure of the Replicative Polymerase PolC Reveals Mode of Action and Mechanism of Resistance of the Anti-CDI Agent Ibezapolstat and Related Inhibitors.\n\nAccording to Dr. Smits: \"Our findings with ibezapolstat regarding the structural biology of DNA pol IIIC inhibitors have important implications for the development of a new family of antibiotics to treat high priority, multi-drug resistant, gram-positive infections\". He further stated: \"I believe that DNA replication is a promising but underexplored target, and this novel class of DNA pol IIIC inhibitors could be an important new tool to address the pandemic of antimicrobial resistance\"\nRobert J. DeLuccia, Executive Chairman of Acurx, stated: \"We are very pleased with the outcome of our collaboration with LUMC which has been exceptionally productive.\" He added: \"This detailed demonstration of the mod...